Aclarion logo

Aclarion(NASDAQ) ACONW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-97%
5 YearN/A
1 Year-25%
1 Month-18%
$0.02
-17.58%
-0.00Today
Aclarion last closing stock price
MetricPriceDate
Last closeUSD 0.022026-10-09
Aclarion stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-29.67%USD 0.032026-10-02
1 month-17.58%USD 0.032026-09-09
3 month-6.22%USD 0.022026-07-10
Year to date-44.33%USD 0.042025-12-31
1 year-25.18%USD 0.032025-10-09
3 year+62.31%USD 0.012023-10-10
Since inception-97.11%USD 0.732022-04-22

Aclarion Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$83.77K

Net Income (TTM)

-$9.20M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.02

Volume

12

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.02 - $0.20

Estimated Earnings Date

Dec 2, 2026

ACONW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aclarion

Aclarion, Inc. is a healthcare technology firm specializing in software development for magnetic resonance spectroscopy (MRS) within the U.S. market. The company’s flagship product is the NOCISCAN-LS Post-Processor suite, which includes tools for quantifying degenerative pain biomarkers and supporting clinical decision-making.

Products and Services
  • NOCISCAN-LS Post-Processor suite for MRS data analysis
  • NOCICALC-LS for quantifying degenerative pain biomarkers
  • NOCIGRAM-LS, a clinical decision support tool
Growth Outlook
  • Increasing demand for advanced healthcare technology solutions
  • Expansion into new markets anticipated in the coming years
  • Focus on enhancing product offerings to improve clinical outcomes
Financial Highlights
  • Q2 2026 revenue of $25,208, a 19% increase from Q1 2026
  • Cash and cash equivalents of $16,285,462 as of June 30, 2026
  • Current ratio of 16.20, indicating strong liquidity position
Aclarion, Inc. has positioned itself in a growing sector of healthcare technology, focusing on innovative solutions that address significant clinical needs. The company's flagship products are designed to enhance diagnostic capabilities and improve patient outcomes, which is increasingly important in today's healthcare landscape. Recent financial performance shows a positive trend in revenue growth, with a notable increase from the previous quarter. The strong liquidity position, reflected in the current ratio, suggests that Aclarion is well-equipped to manage its operational needs and invest in future growth opportunities. As the healthcare industry continues to evolve, Aclarion, Inc. is poised to capitalize on emerging trends and expand its market presence, making it an intriguing option for potential investors interested in healthcare technology.
AI Generated • Oct 5, 2026

Industry

Health Care Technology

Headquarters

Broomfield, CA 80021, US

ACONW Financials

Key Financial Metrics (TTM)

Gross Margin

-50.96%

Operating Margin

-11592.14%

Net Income Margin

-10978.48%

Return on Equity

-59.34%

Return on Capital

-54.95%

Return on Assets

-50.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

12

Avg. Volume

18.32K

Financials (TTM)

Gross Profit

-$42.69K

Operating Income

-$9.71M

EBITDA

-$8.95M

Operating Cash Flow

-$8.09M

Capital Expenditure

$571.00

Free Cash Flow

-$8.09M

Cash & ST Invst.

$16.29M

Total Debt

$0.00

Aclarion Performance Analysis

Aclarion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.0%
Q42025-12-31-2.4%
Q12026-03-3114.4%
Q22026-06-3019.2%
Aclarion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.6%
Q42025-12-3124.6%
Q12026-03-3139.4%
Q22026-06-3016.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$25.21K

+30.5%

Gross Profit

$8.30K

+61.4%

Gross Margin

32.91%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

11

N/A

Net Income

-$2.75M

-71.6%

EBITDA

-$2.69M

-73.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$16.29M

+26.6%

Total Debt

$0.00

N/A

Accounts Receivable

$28.17K

+34.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-50.98%

N/A

Return on Invested Capital

-57.11%

N/A

Free Cash Flow

-$2.61M

-39.7%

Operating Cash Flow

-$2.66M

-42.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDXLMedixall Group, Inc.
$0.00+0.00%
ORHBORHub, Inc.
$0.01+0.00%
OLMMOneLife Technologies Corp.
$0.00+0.00%
APYIAspyra Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About ACONW

What is the current price of Aclarion?

Aclarion is trading at $0.02 per share.

What is the 52-week range for Aclarion?

Over the past 52 weeks, Aclarion has traded between $0.02 and $0.20.

How much debt does Aclarion have?

Aclarion total debt is unavailable.

How much cash does Aclarion have on hand?

Aclarion does not have cash on hand data available.

What is Aclarion’s dividend yield?

Aclarion does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.